ArticleFrontiers in immunology2025
Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Follicular lymphoma is a common B-cell lymphoma and is classified as an indolent lymphoma, more frequently seen in middle-aged and elderly individuals. In recent years, considerable research has been conducted on follicular lymphoma; however, cases of Epstein-Barr virus (EBV)-positive follicular lymphoma remain rare. Notably, follicular lymphoma with EBV positivity accompanied by high PD-L1 expression has not been reported. Case presentation: We present a case of EBV-positive follicular lymphoma with high PD-L1 expression and analyze its clinicopathological features. The patient was treated with R-CHOP chemotherapy combined with the anti-CD20 antibody (rituximab), achieving favorable therapeutic outcomes. This case provides valuable insights for the pathological diagnosis and treatment of EBV-positive follicular lymphoma, as well as the role of EBV infection in PD-L1 expression. Furthermore, it raises the question of whether high PD-L1 expression suggests that immunotherapy could serve as another potential treatment strategy for EBV-positive follicular lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.